Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewSGC-SMARCA-BRDVIII is a selective and high affinity SMARCA2/4 and PB1(bromo 5)-selective SWI/SNF bromodomains inhibitor (Kd(ITC) values are 35, 36 and 13 nM, respectively). SGC-SMARCA-BRDVIII exhibits selectivity over 25 other bromodomain families and shows no off-target activity on 85 protein kinases screened using temperature-shift binding assays. SGC-SMARCA-BRDVIII suppresses formation of 3T3-L1 mouse fibroblasts into adipocytes (EC50 <1.0 μM).
This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the SGC SMARCA-BRDVIII probe summary on the SGC website.
Chemicalprobes.org is a portal that offers independent guidance on the selection and/or application of small molecules for research. The use of SGC-SMARCA-BRDVIII is reviewed on the chemical probes website.
SGC SMARCA-BRDVIII is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen Epigenetics Library. 了解 Tocris 化合物库的更多信息。
分子量 | 371.44 |
公式 | C19H25N5O3 |
储存 | Store at -20°C |
纯度 | ≥98% (HPLC) |
CAS Number | 1997319-84-2 |
PubChem ID | 137045929 |
InChI Key | AQTNUGRRZDRZIA-UHFFFAOYSA-N |
Smiles | CC(C)(OC(N1CCN(C2=C(N=NC(C3=C(C=CC=C3)O)=C2)N)CC1)=O)C |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
DMSO | 37.14 | 100 | |
ethanol | 3.71 | 10 |
以下数据基于产品分子量 371.44。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 2.69 mL | 13.46 mL | 26.92 mL |
5 mM | 0.54 mL | 2.69 mL | 5.38 mL |
10 mM | 0.27 mL | 1.35 mL | 2.69 mL |
50 mM | 0.05 mL | 0.27 mL | 0.54 mL |
参考文献是支持产品生物活性的出版物。
Wanior et al (2020) Pan-SMARCA/PB1 bromodomain inhibitors and their role in regulating adipogenesis. J.Med.Chem. 63 14680 PMID: 33216538
Farnaby et al (2019) BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. Nat.Chem.Biol. 15 672 PMID: 31178587
If you know of a relevant reference for SGC SMARCA-BRDVIII, please let us know.
关键词: SGC SMARCA-BRDVIII, SGC SMARCA-BRDVIII supplier, SGC-SMARCA-BRDVIII, selective, high, affinity, SMARCA2, SMARCA4, PBI, bromo, 5, bromodomains, Bromodomains, Other, ATPases, 7460, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。
目前没有 SGC SMARCA-BRDVIII 的引用文献。 您是否知道使用了 Tocris SGC SMARCA-BRDVIII 的优秀论文? 请告知我们.
目前没有该产品的评论。 Be the first to review SGC SMARCA-BRDVIII and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.